$1M$10M
$1M$10M
$1B$10B
$100M$250M
$25M$50M
$25M$50MImmunomic Therapeutics, Inc. uses 8 technology products and services including Microsoft 365, Twemoji, JSON-LD, and more. Explore Immunomic Therapeutics, Inc.'s tech stack below.
| Immunomic Therapeutics, Inc. Email Formats | Percentage |
| FLast@immunomix.com | 90% |
| First.Last@immunomix.com | 7% |
| FirstLa@immunomix.com | 2% |
| First_Last@immunomix.com | 1% |
Biotechnology ResearchMaryland, United States11-50 Employees
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.
Company Overview
Media & News
Funding & FinancialsImmunomic Therapeutics, Inc. has raised a total of $131M of funding over 3 rounds. Their latest funding round was raised on Apr 23, 2020 in the amount of $61Mas a financing.
Immunomic Therapeutics, Inc.'s revenue is estimated to be in the range of $10M$25M
Funding & FinancialsImmunomic Therapeutics, Inc. has raised a total of $131M of funding over 3 rounds. Their latest funding round was raised on Apr 23, 2020 in the amount of $61Mas a financing.
Immunomic Therapeutics, Inc.'s revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com